To evaluate the efficiency of this combined treatment, both established long-term glioblastoma cell lines U87-MG and p53-deficient U87-MGshp53, as well as primary cultures of ndGBM and rGBM, are used. This evidence concerns the gene TP53 and glioblastoma.